Skip to main
PFE
PFE logo

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 31 analyst ratings
Hold
Strong Buy 23%
Buy 13%
Hold 61%
Sell 3%
Strong Sell 0%

Bulls say

Pfizer reported a strong performance in the fourth quarter of 2024, with revenues exceeding expectations, primarily driven by the sales of key products such as Comirnaty, Paxlovid, Eliquis, and Ibrance. The company maintains an optimistic outlook for fiscal year 2025, emphasizing stabilization in revenues from COVID-19 products while focusing on pipeline opportunities and cost realignment. Management's strategy includes leveraging insights from ongoing clinical updates and exploring business development opportunities, which positions Pfizer favorably for sustained growth in the pharmaceutical sector.

Bears say

The analysis indicates significant risks associated with Pfizer's key marketed products, including disappointing commercial execution and potential regulatory setbacks, which may undermine investor confidence in the company's growth prospects. Furthermore, adjustments to estimated costs of goods sold (COGS) and revenue forecasts for multiple products, including reductions for Padcev and Abrysvo, reflect a cautious future outlook amid ongoing challenges and impairments in sales projections. Lastly, heightened concerns regarding potential US drug pricing reform could adversely impact Pfizer's positioning in the large-cap biopharma sector, adding to the negative sentiment surrounding its stock.

Pfizer (PFE) has been analyzed by 31 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 13% recommend Buy, 61% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 31 analysts, Pfizer (PFE) has a Hold consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.